Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplet low-intensity therapy combinations in older adults with untreated acute myeloid leukemia
ACTRN12619001655134Phase 2Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of venetoclax, cytarabine, midostaurin, pracinostat and azacitidine in acute myeloid leukemia (AML) (6 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Dose-limiting toxicity with midostaurin-containing regimens, Clinical response in randomized phase and 1 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
venetoclaxcytarabinemidostaurinpracinostatazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12619001655134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001655134.